A detailed history of Crewe Advisors LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Crewe Advisors LLC holds 41 shares of TGTX stock, worth $1,271. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41
Holding current value
$1,271
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 16, 2026

BUY
$30.3 - $36.76 $1,242 - $1,507
41 New
41 $1,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.5B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Crewe Advisors LLC Portfolio

Follow Crewe Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crewe Advisors LLC with notifications on news.